US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Alto Neuroscience

2.57

+0.19007.98%

Post-market: 2.570.00000.00%19:55 EDT

Volume:260.89K

Turnover:657.69K

Market Cap:69.58M

PE:-1.10

High:2.60

Open:2.42

Low:2.40

Close:2.38

Loading ...

Overview Company News Filings

Buy Rating for Alto Neuroscience Driven by Strategic Acquisitions and Promising Pipeline Developments

Alto Neuroscience’s Strategic Acquisition and Promising Pipeline Boost Buy Rating

BUZZ-U.S. STOCKS ON THE MOVE-Guardant Health, Hewlett Packard Enterprise, Venture Global

Strategic Acquisition and Promising Clinical Developments Drive Buy Rating for Alto Neuroscience, Inc.

Alto Neuroscience acquires dopamine agonist combination candidate

Alto Neuroscience Acquires Dopamine Agonist Combination ALTO-207 to Enhance Treatment for Resistant Depression

Alto Neuroscience Inc - Chase Therapeutics Eligible for up to $71.5 Mln in Milestone Payments

THOMSON REUTERS

Alto Neuroscience Inc - Phase 2B Trial for Alto-207 Expected by Mid-2026

THOMSON REUTERS

Alto Neuroscience Announces Acquisition of Novel Dopamine Agonist Combination Product Candidate, Adding Late-Stage Readout in Treatment Resistant Depression Within Current Cash Runway

THOMSON REUTERS

Alto Neuroscience Presents Data at the 2025 American Society of Clinical Psychopharmacology Annual Meeting Reinforcing Safety and Tolerability Profile for ALTO-300 in Major Depressive Disorder

Alto Neuroscience Inc. to Participate in Jefferies Global Healthcare Conference

Alto Neuroscience, Inc.: Promising Clinical Trials and Strong Financial Position Justify Buy Rating

Alto Neuroscience Advances Precision Psychiatry Pipeline

Alto Neuroscience Price Target Maintained With a $4.00/Share by Wedbush

BRIEF-Alto Neuroscience Reports First Quarter 2025 Financial Results And Recent Business Highlights

Alto Neuroscience Approves Key Proposals at Annual Meeting

Alto Neuroscience Q1 EPS $(0.56) Beats $(0.61) Estimate

Alto Neuroscience Reports Q1 2025 Net Loss of $15.2 Million, Up from $13.4 Million in Q1 2024; Strong Cash Position Maintained

Alto Neuroscience Reports First Quarter 2025 Financial Results and Recent Business Highlights

THOMSON REUTERS

Press Release: Alto Neuroscience Reports First Quarter 2025 Financial Results and Recent Business Highlights

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/ANRO/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ANRO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ANRO\",,,,,undefined,":{"symbol":"ANRO","market":"US","secType":"STK","nameCN":"Alto Neuroscience","latestPrice":2.57,"timestamp":1749240000000,"preClose":2.38,"halted":0,"volume":260894,"hourTrading":{"tag":"盘后","latestPrice":2.57,"preClose":2.57,"latestTime":"19:55 EDT","volume":1595,"amount":4099.6,"timestamp":1749254143597},"delay":0,"floatShares":17903521,"shares":27072129,"eps":-2.343213,"marketStatus":"Market Closed","change":0.19,"latestTime":"06-06 16:00:00 EDT","open":2.42,"high":2.6,"low":2.4,"amount":657691.728457,"amplitude":0.084034,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.343213,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1749456000000},"marketStatusCode":7,"adr":0,"listingDate":1706850000000,"exchange":"NYSE","adjPreClose":2.38,"preHourTrading":{"tag":"盘前","latestPrice":2.37,"preClose":2.375,"latestTime":"09:19 EDT","volume":1606,"amount":3840.8848676,"timestamp":1749215990371},"postHourTrading":{"tag":"盘后","latestPrice":2.57,"preClose":2.57,"latestTime":"19:55 EDT","volume":1595,"amount":4099.6,"timestamp":1749254143597},"volumeRatio":0.6471959322610765,"impliedVol":2.1905,"impliedVolPercentile":0.4444},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ANRO\",,,,,undefined,":{"symbol":"ANRO","floatShares":17903521,"roa":"-22.88%","roe":"-38.04%","lyrEps":-2.496992,"volumeRatio":0.6471959322610765,"shares":27072129,"dividePrice":0,"high":2.6,"amplitude":0.084034,"preClose":2.38,"low":2.4,"week52Low":1.6,"pbRate":"0.50","week52High":17.55,"institutionHeld":0,"latestPrice":2.57,"eps":-2.343213,"divideRate":0,"volume":260894,"delay":0,"ttmEps":-2.343213,"open":2.42,"prevYearClose":4.23,"prevWeekClose":2.58,"prevMonthClose":2.58,"prevQuarterClose":2.16,"fiveDayClose":2.58,"twentyDayClose":2.19,"sixtyDayClose":3.44},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ANRO\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2541631878","title":"Buy Rating for Alto Neuroscience Driven by Strategic Acquisitions and Promising Pipeline Developments","url":"https://stock-news.laohu8.com/highlight/detail?id=2541631878","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541631878?lang=en_us&edition=fundamental","pubTime":"2025-06-06 21:35","pubTimestamp":1749216922,"startTime":"0","endTime":"0","summary":"Justin Walsh, an analyst from JonesTrading, reiterated the Buy rating on Alto Neuroscience, Inc. (ANRO – Research Report). The associated price tar...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/buy-rating-for-alto-neuroscience-driven-by-strategic-acquisitions-and-promising-pipeline-developments-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/buy-rating-for-alto-neuroscience-driven-by-strategic-acquisitions-and-promising-pipeline-developments-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ANRO"],"gpt_icon":0},{"id":"2540085326","title":"Alto Neuroscience’s Strategic Acquisition and Promising Pipeline Boost Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2540085326","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540085326?lang=en_us&edition=fundamental","pubTime":"2025-06-04 08:05","pubTimestamp":1748995513,"startTime":"0","endTime":"0","summary":"William Blair analyst Myles Minter has maintained their bullish stance on ANRO stock, giving a Buy rating yesterday. Myles Minter has given his Buy...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/alto-neurosciences-strategic-acquisition-and-promising-pipeline-boost-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/alto-neurosciences-strategic-acquisition-and-promising-pipeline-boost-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ANRO"],"gpt_icon":0},{"id":"2540709879","title":"BUZZ-U.S. STOCKS ON THE MOVE-Guardant Health, Hewlett Packard Enterprise, Venture Global","url":"https://stock-news.laohu8.com/highlight/detail?id=2540709879","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540709879?lang=en_us&edition=fundamental","pubTime":"2025-06-04 01:42","pubTimestamp":1748972559,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Guardant Health, Hewlett Packard Enterprise, Venture GlobalEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morn","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250603:nL6N3S60GT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2286300806.USD","LU2125154778.USD","OSK","HPE","LU2290526834.HKD","DVN","LU1064131342.USD","SIG","BK4015","LU0985489474.SGD","CVX","DG","LIF","SG9999001143.SGD","ANRO","GH","NEM","LU1988902786.USD","LU2211817866.USD","BEAM","XOM","BMBL","WWD","IE00BGHQF524.EUR","LU1978683503.SGD","IE00BD4GTW91.USD","FCX","KYMR","STRK","XYZ","AGEN","SCCO","VG","LU1951198990.SGD","PINS","STR","FDX"],"gpt_icon":1},{"id":"2540570834","title":"Strategic Acquisition and Promising Clinical Developments Drive Buy Rating for Alto Neuroscience, Inc.","url":"https://stock-news.laohu8.com/highlight/detail?id=2540570834","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540570834?lang=en_us&edition=fundamental","pubTime":"2025-06-03 22:35","pubTimestamp":1748961312,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Alto Neuroscience, Inc. (ANRO – Research Report) today and set a price target o...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/strategic-acquisition-and-promising-clinical-developments-drive-buy-rating-for-alto-neuroscience-inc-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/strategic-acquisition-and-promising-clinical-developments-drive-buy-rating-for-alto-neuroscience-inc-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ANRO"],"gpt_icon":0},{"id":"2540778113","title":"Alto Neuroscience acquires dopamine agonist combination candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2540778113","media":"TIPRANKS","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540778113?lang=en_us&edition=fundamental","pubTime":"2025-06-03 18:10","pubTimestamp":1748945430,"startTime":"0","endTime":"0","summary":"Alto Neuroscience (ANRO) entered into an asset purchase agreement with Chase Therapeutics for a portfolio of potentially best-in-class dopamine ago...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/alto-neuroscience-acquires-dopamine-agonist-combination-candidate-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/alto-neuroscience-acquires-dopamine-agonist-combination-candidate-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","ANRO"],"gpt_icon":0},{"id":"2540094720","title":"Alto Neuroscience Acquires Dopamine Agonist Combination ALTO-207 to Enhance Treatment for Resistant Depression","url":"https://stock-news.laohu8.com/highlight/detail?id=2540094720","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540094720?lang=en_us&edition=fundamental","pubTime":"2025-06-03 18:03","pubTimestamp":1748945002,"startTime":"0","endTime":"0","summary":"Alto Neuroscience, Inc., a clinical-stage biopharmaceutical company, announced the acquisition of a portfolio of dopamine agonist drug combinations from Chase Therapeutics Corporation. This includes ALTO-207, formerly known as CTC-501, aimed at treating treatment-resistant depression . The acquisition aligns with Alto's mission to innovate in psychiatry by advancing ALTO-207, which combines pramipexole and ondansetron to deliver rapid antidepressant effects while minimizing adverse events. Alto plans to leverage its proprietary insights on dopamine biomarkers to further develop this promising treatment, with a Phase 2b trial anticipated by mid-2026. The transaction supports Alto's strategic expansion without altering its cash runway guidance into 2028.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and shou","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250603:nNDLtgrWy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ANRO"],"gpt_icon":0},{"id":"2540720090","title":"Alto Neuroscience Inc - Chase Therapeutics Eligible for up to $71.5 Mln in Milestone Payments","url":"https://stock-news.laohu8.com/highlight/detail?id=2540720090","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540720090?lang=en_us&edition=fundamental","pubTime":"2025-06-03 18:03","pubTimestamp":1748944980,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250603:nTUA6RF3ZS:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ANRO","BK4007"],"gpt_icon":0},{"id":"2540720012","title":"Alto Neuroscience Inc - Phase 2B Trial for Alto-207 Expected by Mid-2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2540720012","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540720012?lang=en_us&edition=fundamental","pubTime":"2025-06-03 18:03","pubTimestamp":1748944980,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250603:nTUA6RF3ZS:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ANRO","BK4007"],"gpt_icon":0},{"id":"2540209097","title":"Alto Neuroscience Announces Acquisition of Novel Dopamine Agonist Combination Product Candidate, Adding Late-Stage Readout in Treatment Resistant Depression Within Current Cash Runway","url":"https://stock-news.laohu8.com/highlight/detail?id=2540209097","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540209097?lang=en_us&edition=fundamental","pubTime":"2025-06-03 18:03","pubTimestamp":1748944980,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250603:nTUA6RF3ZS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ANRO"],"gpt_icon":0},{"id":"2539295647","title":"Alto Neuroscience Presents Data at the 2025 American Society of Clinical Psychopharmacology Annual Meeting Reinforcing Safety and Tolerability Profile for ALTO-300 in Major Depressive Disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2539295647","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539295647?lang=en_us&edition=fundamental","pubTime":"2025-05-29 20:03","pubTimestamp":1748520180,"startTime":"0","endTime":"0","summary":"– Convergent clinical and preclinical evidence supports the mechanistic link between ALTO-300 and the biomarker, a measure of greater EEG irregularity, being used for patient selection –。– Completed Phase 2a and ongoing Phase 2b trial of ALTO-300 in MDD underscore favorable tolerability profile for 25mg dose –。MOUNTAIN VIEW, Calif., May 29, 2025----Alto Neuroscience, Inc.   a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced a presentation at the American Society of Clinical Psychopharmacology  Annual Meeting, in Scottsdale, Arizona, held May 27-30, 2025.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/alto-neuroscience-presents-data-2025-120300913.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4110","BK4117","ALTO","LFT","BK4138","BK4107","BK4007","AFG","ANRO","BK4109"],"gpt_icon":0},{"id":"2538730074","title":"Alto Neuroscience Inc. to Participate in Jefferies Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2538730074","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538730074?lang=en_us&edition=fundamental","pubTime":"2025-05-28 20:03","pubTimestamp":1748433792,"startTime":"0","endTime":"0","summary":"Alto Neuroscience Inc., a clinical-stage biopharmaceutical company focused on developing novel precision medicines for neuropsychiatric disorders, is set to participate in the Jefferies Global Healthcare Conference from June 3-5, 2025. The company's management team will engage in a fireside chat and hold one-on-one investor meetings, with their presentation scheduled for June 5, 2025, at 2:00 pm ET at the New York Marriott Marquis.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alto Neuroscience Inc. published the original content used to generate this news brief via Business Wire  on May 28, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250528:nNDL9FmdBr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANRO","BK4007"],"gpt_icon":0},{"id":"2536483745","title":"Alto Neuroscience, Inc.: Promising Clinical Trials and Strong Financial Position Justify Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2536483745","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536483745?lang=en_us&edition=fundamental","pubTime":"2025-05-19 08:15","pubTimestamp":1747613717,"startTime":"0","endTime":"0","summary":"TD Cowen analyst Ritu Baral has maintained their bullish stance on ANRO stock, giving a Buy rating on May 15. Ritu Baral has given her Buy rating d...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/alto-neuroscience-inc-promising-clinical-trials-and-strong-financial-position-justify-buy-rating?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/alto-neuroscience-inc-promising-clinical-trials-and-strong-financial-position-justify-buy-rating?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ANRO"],"gpt_icon":0},{"id":"2535339720","title":"Alto Neuroscience Advances Precision Psychiatry Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2535339720","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535339720?lang=en_us&edition=fundamental","pubTime":"2025-05-16 12:31","pubTimestamp":1747369909,"startTime":"0","endTime":"0","summary":"Alto Neuroscience, Inc. ( ($ANRO) ) has released its Q1 earnings. Here is a breakdown of the information Alto Neuroscience, Inc. presented to its i...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/alto-neuroscience-advances-precision-psychiatry-pipeline?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/alto-neuroscience-advances-precision-psychiatry-pipeline?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","ANRO"],"gpt_icon":0},{"id":"2535582780","title":"Alto Neuroscience Price Target Maintained With a $4.00/Share by Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2535582780","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535582780?lang=en_us&edition=fundamental","pubTime":"2025-05-15 22:58","pubTimestamp":1747321080,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ANRO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 15, 2025 10:58 ET (14:58 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANRO"],"gpt_icon":0},{"id":"2535883067","title":"BRIEF-Alto Neuroscience Reports First Quarter 2025 Financial Results And Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2535883067","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535883067?lang=en_us&edition=fundamental","pubTime":"2025-05-15 05:21","pubTimestamp":1747257687,"startTime":"0","endTime":"0","summary":"BRIEF-Alto Neuroscience Reports First Quarter 2025 Financial Results And Recent Business HighlightsMay 14 (Reuters) - Alto Neuroscience Inc ANRO.N:ALTO NEUROSCIENCE REPORTS FIRST QUARTER 2025 FINANCIA","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250514:nTUA2YJQ4K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ANRO"],"gpt_icon":0},{"id":"2535883271","title":"Alto Neuroscience Approves Key Proposals at Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2535883271","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535883271?lang=en_us&edition=fundamental","pubTime":"2025-05-15 05:09","pubTimestamp":1747256948,"startTime":"0","endTime":"0","summary":"Alto Neuroscience, Inc. ( ($ANRO) ) has issued an announcement. On May 13, 2025, Alto Neuroscience held its annual meeting of stockholders, where t...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/alto-neuroscience-approves-key-proposals-at-annual-meeting?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/alto-neuroscience-approves-key-proposals-at-annual-meeting?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ANRO","BK4007"],"gpt_icon":0},{"id":"2535800700","title":"Alto Neuroscience Q1 EPS $(0.56) Beats $(0.61) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2535800700","media":"Benzinga","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535800700?lang=en_us&edition=fundamental","pubTime":"2025-05-15 04:25","pubTimestamp":1747254357,"startTime":"0","endTime":"0","summary":"Alto Neuroscience (NYSE:ANRO) reported quarterly losses of $(0.56) per share which beat the analyst consensus estimate of $(0.61) by 8.2 percent. This is a 26.32 percent increase over losses of $(0.76) per share from the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/05/45421050/alto-neuroscience-q1-eps-0-56-beats-0-61-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANRO"],"gpt_icon":0},{"id":"2535429007","title":"Alto Neuroscience Reports Q1 2025 Net Loss of $15.2 Million, Up from $13.4 Million in Q1 2024; Strong Cash Position Maintained","url":"https://stock-news.laohu8.com/highlight/detail?id=2535429007","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535429007?lang=en_us&edition=fundamental","pubTime":"2025-05-15 04:19","pubTimestamp":1747253958,"startTime":"0","endTime":"0","summary":"Alto Neuroscience Reports Q1 2025 Net Loss of $15.2 Million, Up from $13.4 Million in Q1 2024; Strong Cash Position Maintained. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alto Neuroscience Inc. published the original content used to generate this news brief via Business Wire  on May 14, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250514:nNDLWXgdr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANRO","BK4007"],"gpt_icon":0},{"id":"2535007353","title":"Alto Neuroscience Reports First Quarter 2025 Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2535007353","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535007353?lang=en_us&edition=fundamental","pubTime":"2025-05-15 04:10","pubTimestamp":1747253400,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250514:nTUA2YJQ4K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ANRO"],"gpt_icon":0},{"id":"2535007372","title":"Press Release: Alto Neuroscience Reports First Quarter 2025 Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2535007372","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535007372?lang=en_us&edition=fundamental","pubTime":"2025-05-15 04:10","pubTimestamp":1747253400,"startTime":"0","endTime":"0","summary":"-- Phase 2 proof-of-concept trials remain on track: Topline data expected from ALTO-203 in MDD in the second quarter of 2025 followed by ALTO-101 in schizophrenia in the second half of 2025 --. -- Late-stage programs advancing: Topline data expected from the Phase 2b trial of ALTO-300 in MDD in mid-2026 followed by the Phase 2b trial of ALTO-100 in bipolar depression in the second half of 2026 --. -- New data presented at recent scientific conferences support Alto's biomarker-driven pipeline and patient stratification approach --. -- Strong cash position of approximately $161.3 million expected to fund planned operations into 2028, and through at least four upcoming clinical study readouts --. 2026. The Company expects to enroll approximately 200 patients with BPD.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVC","ANRO","LFT","BK4139","BK4007","BK4110"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":63,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ANRO\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ANRO\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ANRO\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.375,"hold":0.125,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.375,"analysts":8,"updateTime":1744084800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ANRO\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ANRO","date":"2025-06-06","current":-1.019763,"percent":0.930599,"low":-16.978804,"twenty":-10.071835,"median":-5.469741,"eighty":-1.461958,"high":-0.793245,"avg":-5.387247,"sd":4.104858,"marketCap":64431667},"quantilePoints":[{"date":"2024-02-09","current":-15.481605,"twenty":-16.048587,"median":-15.481605,"eighty":-13.872658,"marketCap":506867732},{"date":"2024-02-16","current":-12.96931,"twenty":-15.548491,"median":-13.234406,"eighty":-11.571235,"marketCap":424615224},{"date":"2024-02-23","current":-10.603839,"twenty":-15.481605,"median":-12.585941,"eighty":-11.026361,"marketCap":347169680},{"date":"2024-03-01","current":-12.56147,"twenty":-14.292343,"median":-12.488059,"eighty":-11.135662,"marketCap":411262544},{"date":"2024-03-08","current":-11.631595,"twenty":-13.230328,"median":-12.361629,"eighty":-11.293904,"marketCap":380818433},{"date":"2024-03-15","current":-12.153631,"twenty":-13.001937,"median":-12.137317,"eighty":-11.306955,"marketCap":397909864},{"date":"2024-03-22","current":-11.14409,"twenty":-12.949734,"median":-12.108768,"eighty":-11.306955,"marketCap":404586204},{"date":"2024-03-28","current":-12.415912,"twenty":-12.956259,"median":-12.145474,"eighty":-11.437463,"marketCap":450759680},{"date":"2024-04-05","current":-10.418119,"twenty":-12.920369,"median":-11.868143,"eighty":-11.162905,"marketCap":378229815},{"date":"2024-04-12","current":-10.440317,"twenty":-12.863272,"median":-11.793418,"eighty":-10.823597,"marketCap":379035702},{"date":"2024-04-19","current":-9.988964,"twenty":-12.713187,"median":-11.631595,"eighty":-10.532067,"marketCap":362649325},{"date":"2024-04-26","current":-10.455115,"twenty":-12.538631,"median":-11.566341,"eighty":-10.461035,"marketCap":379572960},{"date":"2024-05-03","current":-10.654895,"twenty":-12.497847,"median":-11.513206,"eighty":-10.478793,"marketCap":386825947},{"date":"2024-05-10","current":-10.802879,"twenty":-12.4592,"median":-11.360121,"eighty":-10.478793,"marketCap":392198529},{"date":"2024-05-17","current":-8.114957,"twenty":-12.377436,"median":-11.191128,"eighty":-10.431438,"marketCap":344382544},{"date":"2024-05-24","current":-7.443985,"twenty":-12.295701,"median":-11.079356,"eighty":-10.270134,"marketCap":315907856},{"date":"2024-05-31","current":-7.59948,"twenty":-12.254775,"median":-10.943138,"eighty":-9.999323,"marketCap":322506720},{"date":"2024-06-07","current":-7.453823,"twenty":-12.218885,"median":-10.773282,"eighty":-9.088414,"marketCap":316325341},{"date":"2024-06-14","current":-7.612146,"twenty":-12.153631,"median":-10.654895,"eighty":-8.114957,"marketCap":323044231},{"date":"2024-06-21","current":-6.997854,"twenty":-12.14058,"median":-10.580902,"eighty":-7.890353,"marketCap":296974938},{"date":"2024-06-28","current":-6.731872,"twenty":-12.125897,"median":-10.558705,"eighty":-7.854905,"marketCap":285687202},{"date":"2024-07-05","current":-7.35883,"twenty":-12.080219,"median":-10.514309,"eighty":-7.738804,"marketCap":312294007},{"date":"2024-07-12","current":-8.486086,"twenty":-11.912764,"median":-10.492111,"eighty":-7.738804,"marketCap":360132504},{"date":"2024-07-15","current":-8.840728,"twenty":-11.90384,"median":-10.492111,"eighty":-7.738804,"marketCap":375182817},{"date":"2024-08-02","current":-6.212575,"twenty":-11.894916,"median":-10.481012,"eighty":-7.674208,"marketCap":263649243},{"date":"2024-08-09","current":-5.762939,"twenty":-11.86488,"median":-10.440317,"eighty":-7.584281,"marketCap":244567596},{"date":"2024-08-16","current":-5.077305,"twenty":-11.842621,"median":-10.421819,"eighty":-7.439715,"marketCap":252875166},{"date":"2024-08-23","current":-5.770157,"twenty":-11.798049,"median":-10.270134,"eighty":-7.320833,"marketCap":287382652},{"date":"2024-08-30","current":-6.766131,"twenty":-11.747422,"median":-10.066655,"eighty":-7.023186,"marketCap":336987162},{"date":"2024-09-06","current":-6.885215,"twenty":-11.696849,"median":-9.985264,"eighty":-6.997854,"marketCap":342918136},{"date":"2024-09-13","current":-7.036776,"twenty":-11.629964,"median":-9.589405,"eighty":-7.005638,"marketCap":350466649},{"date":"2024-09-20","current":-7.269531,"twenty":-11.615282,"median":-8.800669,"eighty":-7.041657,"marketCap":362059007},{"date":"2024-09-27","current":-6.495486,"twenty":-11.576129,"median":-8.327763,"eighty":-6.997854,"marketCap":323507676},{"date":"2024-10-04","current":-5.51575,"twenty":-11.542663,"median":-8.073812,"eighty":-6.792939,"marketCap":274711934},{"date":"2024-10-11","current":-6.392641,"twenty":-11.505807,"median":-7.947789,"eighty":-6.506312,"marketCap":318385471},{"date":"2024-10-18","current":-7.724215,"twenty":-11.453451,"median":-7.863613,"eighty":-6.586066,"marketCap":384704544},{"date":"2024-10-25","current":-2.23553,"twenty":-11.361501,"median":-7.821648,"eighty":-6.506312,"marketCap":111340558},{"date":"2024-10-31","current":-2.181401,"twenty":-11.357822,"median":-7.776801,"eighty":-6.403467,"marketCap":108644661},{"date":"2024-11-08","current":-2.083968,"twenty":-11.223755,"median":-7.738804,"eighty":-6.212575,"marketCap":103792046},{"date":"2024-11-15","current":-2.159604,"twenty":-11.191128,"median":-7.724215,"eighty":-6.11117,"marketCap":124062772},{"date":"2024-11-22","current":-1.92017,"twenty":-11.14409,"median":-7.634377,"eighty":-5.98126,"marketCap":110307987},{"date":"2024-11-29","current":-2.070403,"twenty":-11.113816,"median":-7.615312,"eighty":-5.768005,"marketCap":118938440},{"date":"2024-12-06","current":-1.830969,"twenty":-11.06322,"median":-7.574148,"eighty":-5.648645,"marketCap":105183655},{"date":"2024-12-13","current":-1.798105,"twenty":-11.000259,"median":-7.504253,"eighty":-5.44863,"marketCap":103295743},{"date":"2024-12-20","current":-1.746462,"twenty":-10.916697,"median":-7.443985,"eighty":-5.07514,"marketCap":100329024},{"date":"2024-12-27","current":-2.075098,"twenty":-10.841355,"median":-7.436869,"eighty":-2.363274,"marketCap":119208142},{"date":"2025-01-03","current":-2.056319,"twenty":-10.79104,"median":-7.390494,"eighty":-2.255016,"marketCap":118129335},{"date":"2025-01-10","current":-2.070403,"twenty":-10.767363,"median":-7.35883,"eighty":-2.165554,"marketCap":118938440},{"date":"2025-01-17","current":-2.079793,"twenty":-10.725927,"median":-7.312287,"eighty":-2.141345,"marketCap":119477844},{"date":"2025-01-24","current":-2.272279,"twenty":-10.654895,"median":-7.277651,"eighty":-2.138097,"marketCap":130535613},{"date":"2025-01-31","current":-2.093877,"twenty":-10.603839,"median":-7.253293,"eighty":-2.122046,"marketCap":120286949},{"date":"2025-02-07","current":-1.854443,"twenty":-10.580902,"median":-7.17813,"eighty":-2.093877,"marketCap":106532163},{"date":"2025-02-14","current":-1.530502,"twenty":-10.558705,"median":-7.145034,"eighty":-2.075098,"marketCap":87922747},{"date":"2025-02-21","current":-1.464775,"twenty":-10.529107,"median":-7.061183,"eighty":-2.070403,"marketCap":84146924},{"date":"2025-02-28","current":-1.305152,"twenty":-10.515789,"median":-6.997854,"eighty":-2.041295,"marketCap":74977067},{"date":"2025-03-07","current":-1.854443,"twenty":-10.50839,"median":-6.933931,"eighty":-2.023455,"marketCap":106532163},{"date":"2025-03-14","current":-1.483554,"twenty":-10.495071,"median":-6.768,"eighty":-2.01289,"marketCap":85225730},{"date":"2025-03-21","current":-1.180996,"twenty":-10.492111,"median":-6.549615,"eighty":-1.993408,"marketCap":72549751},{"date":"2025-03-28","current":-1.062067,"twenty":-10.474353,"median":-6.422411,"eighty":-1.971812,"marketCap":65243830},{"date":"2025-04-04","current":-0.81528,"twenty":-10.458075,"median":-6.392641,"eighty":-1.92017,"marketCap":50083438},{"date":"2025-04-11","current":-0.903418,"twenty":-10.443277,"median":-6.253891,"eighty":-1.873222,"marketCap":55497864},{"date":"2025-04-17","current":-0.991556,"twenty":-10.440317,"median":-6.19297,"eighty":-1.833785,"marketCap":60912290},{"date":"2025-04-25","current":-1.004777,"twenty":-10.431438,"median":-6.11117,"eighty":-1.798105,"marketCap":61724454},{"date":"2025-05-02","current":-1.079695,"twenty":-10.421079,"median":-6.037568,"eighty":-1.742706,"marketCap":66326716},{"date":"2025-05-09","current":-0.965115,"twenty":-10.40924,"median":-5.975847,"eighty":-1.645994,"marketCap":59287962},{"date":"2025-05-16","current":-1.041186,"twenty":-10.323409,"median":-5.766106,"eighty":-1.583083,"marketCap":65785273},{"date":"2025-05-23","current":-1.255422,"twenty":-10.270134,"median":-5.686944,"eighty":-1.500455,"marketCap":79321337},{"date":"2025-05-30","current":-1.152589,"twenty":-10.199102,"median":-5.617282,"eighty":-1.480737,"marketCap":72824027},{"date":"2025-06-06","current":-1.019763,"twenty":-10.071835,"median":-5.469741,"eighty":-1.461958,"marketCap":64431667}],"updateTime":1749392547477}}}